Andreas Argyrides
Stock Analyst at Wedbush
(4.30)
# 336
Out of 4,784 analysts
100
Total ratings
47.06%
Success rate
18.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Downgrades: Neutral | $47 → $15 | $10.79 | +39.02% | 8 | Jan 17, 2025 | |
| ASND Ascendis Pharma | Reiterates: Outperform | $181 | $154.68 | +17.02% | 9 | Nov 15, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $35 | $13.43 | +160.61% | 1 | Oct 16, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $26 | $2.35 | +1,006.38% | 1 | Oct 16, 2024 | |
| RGLS Regulus Therapeutics | Reiterates: Outperform | $7 | $1.73 | +304.62% | 1 | Aug 14, 2024 | |
| RANI Rani Therapeutics Holdings | Initiates: Outperform | $17 | $1.36 | +1,150.00% | 4 | Aug 2, 2024 | |
| LQDA Liquidia | Initiates: Perform | n/a | $15.09 | - | 6 | Jun 25, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | $104 | $39.86 | +160.91% | 14 | Jun 25, 2024 | |
| CLSD Clearside Biomedical | Initiates: Outperform | $5 | $0.95 | +426.32% | 1 | Jun 25, 2024 | |
| GOSS Gossamer Bio | Initiates: Outperform | $9 | $1.17 | +669.23% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $12.49 | +52.12% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $9 | $3.02 | +198.01% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $19.18 | +51.20% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $7.83 | +168.20% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $70.41 | +218.14% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $24.91 | +128.82% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.14 | - | 6 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $1.20 | +483.33% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $5.03 | +98.81% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.82 | +1,119.51% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $71.44 | -2.02% | 6 | Aug 1, 2023 |
Keros Therapeutics
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $10.79
Upside: +39.02%
Ascendis Pharma
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $154.68
Upside: +17.02%
Benitec Biopharma
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $13.43
Upside: +160.61%
Larimar Therapeutics
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $2.35
Upside: +1,006.38%
Regulus Therapeutics
Aug 14, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.73
Upside: +304.62%
Rani Therapeutics Holdings
Aug 2, 2024
Initiates: Outperform
Price Target: $17
Current: $1.36
Upside: +1,150.00%
Liquidia
Jun 25, 2024
Initiates: Perform
Price Target: n/a
Current: $15.09
Upside: -
MoonLake Immunotherapeutics
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $39.86
Upside: +160.91%
Clearside Biomedical
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.95
Upside: +426.32%
Gossamer Bio
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $1.17
Upside: +669.23%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $12.49
Upside: +52.12%
Mar 7, 2024
Maintains: Outperform
Price Target: $4 → $9
Current: $3.02
Upside: +198.01%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $19.18
Upside: +51.20%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $7.83
Upside: +168.20%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $70.41
Upside: +218.14%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $24.91
Upside: +128.82%
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.14
Upside: -
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $1.20
Upside: +483.33%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $5.03
Upside: +98.81%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.82
Upside: +1,119.51%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $71.44
Upside: -2.02%